Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most common mutation, yet patients with th...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Rubinstein, Jill C, Sznol, Mario, Pavlick, Anna C, Ariyan, Stephan, Cheng, Elaine, Bacchiocchi, Antonella, Kluger, Harriet M, Narayan, Deepak, Halaban, Ruth
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2010
Sujets:
Commentary
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917408/
https://ncbi.nlm.nih.gov/pubmed/20630094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-8-67
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires